To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
(+)-Discodermolide is a recently discovered polyketide natural product found to be a potent inhibitor of tumor cell growth. The molecule's carbon skeleton is made up of eight polypropionate and four acetate units with 13 stereocenters.
Additional recommended knowledge
Discodermolide was first isolated in 1990 from the Caribbean marine sponge Discodermia dissoluta by chemist Dr. Sarath Gunasekera and biologist Dr. Ross Longley, scientists at the Harbor Branch Oceanographic Institution.antifungal activities.The sponge contained 0.002% of discodermolide (7 mg/434 g of sponge). Since the compound is light-sensitive, the sponge must be harvested at a minimum depth of 33 meters. Discodermolide was initially found to have immunosuppressive and
Mechanism of action
Discodermolide has been shown to inhibit the proliferation of human cells by arresting the cell cycle in G2- and M-phase. It hyper-stabilizes microtubules, especially prevalent during cell division, and competes with paclitaxel for microtubule binding, but with higher affinity. Over a variety of cell lines, activity has been measured at IC50 = 3-80 nM.
Hyper-stabilization of the mitotic spindle causes cell cycle arrest and cell death by apoptosis.
Discodermolide is effective in paclitaxel- and epothilone-resistant cancer cells.
Several total syntheses have been published to date by Schreiber , Smith , Paterson , Marshall , and Myles . A review of the various synthetic approaches has also been published.
The Harbor Branch Oceanographic Institution licensed (+)-discodermolide to Novartis, which began a phase 1 clinical trial in 2004. Patient accrual was halted due to drug toxicitiy. The Amos B. Smith's research group (in collaboration with Kosan Biosciences) has a preclinical drug development program ongoing.
The compound supply necessary for complete clinical trials cannot be met by harvesting, isolation, and purification. As of 2005, attempts at synthesis or semi-synthesis by fermentation have proven unsuccessful. As a result, all discodermolide used in preclinical studies and clinical trials has come from large-scale total synthesis.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Discodermolide". A list of authors is available in Wikipedia.|